TrytosaveabitJESSE JAMES8832OP:
Well one thing I can say right off! I’ve been just peeking in on it for a couple weeks and it’s been on a great uptrend for some time now!
TrytosaveabitJESSE JAMES8832OP:
So besides the beautiful uptrend! We’ve got Lots of buys recently from the likes of EcoR1 Capital, Barker Bros Advisors, Redmile Group, Morgan Stanley Capital Services and BlackRock! To name a few! Also a number of individual Buys that are big enough that they are required to repost as well! So this along with the highlights I’m posting! I think this would fit in my category of a long term swing! Really curious for latest earnings? If they are like the last? Could get even better boost? Only thing I have against and it’s definitely not a dealbreaker. Is I don’t see any great chance for updates besides earnings for a little while? Unless it’s a surprise? At least in next 30 days? Again not a big deal to me for what I’m seeing! Here’s some highlights! Company well-positioned for further progress and broadening of R&D pipeline
Cash resources of approximately $455 million as of December 31, 2023 (unaudited)
Expected cash runway, including proceeds from recent private placement, into 2H 2027
Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024
Expected regulatory reviews ongoing during 2024 for zanidatamab in second-line biliary tract cancers (BTC) in the United States and China with our partners Jazz Pharmaceuticals and BeiGene
Expected Investigational New Drug (IND) applications and first-in-human (FIH) studies for ZW171 and ZW191 candidates in 2024 and ZW220 and ZW251 in 2025
Progression on ‘5 by 5’ portfolio and ADVANCE with R&D Day scheduled for Q4-24! Hope this helps my friend
JESSE JAMES8832OP : can i get your opinion when u get a min @Trytosaveabit
Trytosaveabit JESSE JAMES8832OP: Yup yup! I’ll take a look brother
JESSE JAMES8832OP Trytosaveabit: appreciated im looking into it also but i like to get your opinion on things also. lool
Trytosaveabit JESSE JAMES8832OP: Well one thing I can say right off! I’ve been just peeking in on it for a couple weeks and it’s been on a great uptrend for some time now!
JESSE JAMES8832OP Trytosaveabit: 4 months now
Trytosaveabit JESSE JAMES8832OP: So besides the beautiful uptrend! We’ve got Lots of buys recently from the likes of EcoR1 Capital, Barker Bros Advisors, Redmile Group, Morgan Stanley Capital Services and BlackRock! To name a few! Also a number of individual Buys that are big enough that they are required to repost as well! So this along with the highlights I’m posting! I think this would fit in my category of a long term swing! Really curious for latest earnings? If they are like the last? Could get even better boost? Only thing I have against and it’s definitely not a dealbreaker. Is I don’t see any great chance for updates besides earnings for a little while? Unless it’s a surprise? At least in next 30 days? Again not a big deal to me for what I’m seeing! Here’s some highlights!
Company well-positioned for further progress and broadening of R&D pipeline
Cash resources of approximately $455 million as of December 31, 2023 (unaudited)
Expected cash runway, including proceeds from recent private placement, into 2H 2027
Top-line data readout from the Phase 3 trial evaluating zanidatamab in HER2-positive gastroesophageal adenocarcinoma (GEA), HERIZON-GEA-01, expected in 2024
Expected regulatory reviews ongoing during 2024 for zanidatamab in second-line biliary tract cancers (BTC) in the United States and China with our partners Jazz Pharmaceuticals and BeiGene
Expected Investigational New Drug (IND) applications and first-in-human (FIH) studies for ZW171 and ZW191 candidates in 2024 and ZW220 and ZW251 in 2025
Progression on ‘5 by 5’ portfolio and ADVANCE with R&D Day scheduled for Q4-24!
Hope this helps my friend